Pentamidine Isethionate

喷他脒依西酸盐

Report date: 2026/03/11 20:02:12
NME

Base Information

Drug NamePentamidine Isethionate
Drug Alias Name异硫代羟酸戊脒pentamidina羟乙磺酸喷他脒Pentamidinum羟乙磺酸戊双脒 +[23] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEndonucleases inhibitorsExonuclease inhibitors
TargetsEndonucleasesExonuclease
Therapy Area/IndicationsSkin MelanomaFatty LiverPancreatic Neoplasms +[9] 
Global Approved IndicationsPneumonia, Pneumocystis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1984/10/16
Country/TerritoryCanadaUnited StatesPuerto Rico +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesFresenius Kabi Ag
China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Tropical Medicine AntwerpFresenius Kabi Manufacturing Sa
Inactive CompaniesUniversity of Texas Southwestern Medical CenterUniversity Of LouisvilleUniversity Of Maryland, Baltimore +[5] 
Active IndicationsLeishmaniasis, CutaneousPneumonia, Pneumocystis
Inactive IndicationsSkin MelanomaFatty LiverPancreatic Neoplasms +[7] 

Other Information

ATC CodeP01CX01
Related LinksWikipediaDrugBankKEGG